Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

2013/08/22 by Paula L. McClean, Christian Hölscher · 28 citations
Medicine · Neuroscience · #Alzheimer's disease research and treatments #Diabetes Treatment and Management #Nuclear Receptors and Signaling

paper · doi:10.1016/j.neuropharm.2013.08.005

Cited by

• Reduction of Neuroinflammation as a Common Mechanism of Action of Anorexigenic and Orexigenic Peptide Analogues in the Triple Transgenic Mouse Model of Alzheimer´s Disease
• The role of glucagon-like peptides in osteosarcopenia
• The promise of GLP-1 receptor agonists for neurodegenerative diseases
• The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. [europepmc]
• Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. [europepmc]
• Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. [europepmc]
• Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. [europepmc]
• Rodent models for Alzheimer's disease drug discovery. [europepmc]
• Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. [europepmc]
• In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. [europepmc]
• The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. [europepmc]
• Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice. [europepmc]
• Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications. [europepmc]
• Insulin Resistance in Alzheimer's Disease. [europepmc]
• Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. [europepmc]
• Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease. [europepmc]
• Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. [europepmc]
• Type 3 Diabetes and Its Role Implications in Alzheimer's Disease. [europepmc]
• Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. [europepmc]
• Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain. [europepmc]
• Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. [europepmc]
• Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. [europepmc]
• Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. [europepmc]
• GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. [europepmc]
• The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review. [europepmc]
• Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease. [europepmc]
• The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease. [europepmc]
• Mitochondrial Dysfunction: A Key Player in Brain Aging and Diseases. [europepmc]